Morocco's legal cannabis industry has reached a new stage in its development with its first international sale of a cannabis-based drug. Beldiya Plus°, developed by the Moroccan laboratory CANNAFLEX from locally cultivated cannabis, was prescribed and delivered to a patient in South Africa on October 17.
The company announced the sale in a statement published on October 20, calling it a historic milestone for Morocco's nascent legal cannabis industry on the international market. The export was made possible through a strategic partnership with South African pharmaceutical manufacturer DRA Pharmaceuticals, which specializes in compliance and pharmaceutical quality.
"Our advanced pharmaceutical laboratories and expertise are essential to ensure that Beldiya Plus° meets the strictest international standards. This partnership with CANNAFLEX revolutionizes access to medical cannabis by offering patients safe, reliable, and evidence-based therapies," said Chris Hutton, CEO of DRA Pharmaceuticals.
The collaboration highlights how Moroccan producers are aligning with international regulations to access foreign markets. Industry observers see this as a critical validation of Morocco's ability to deliver compliant, research-backed medical cannabis products beyond its borders.
Read more at Ecofin Agency
